论文部分内容阅读
目的 :探讨联合检测人附睾分泌蛋白4(human epididymis secretory protein 4,HE4)和糖类抗原125(carbohydrate antigen,CA125)对卵巢癌的诊断价值。方法 :采用流式荧光发光法分别检测54例卵巢癌患者、94例卵巢良性疾病患者和70例正常对照者血清中的HE4和CA125水平,分析单一和联合检测诊断卵巢癌的价值。结果:联合检测血清HE4和CA125时,以二者其中之一高于参考值即视为阳性,检测的灵敏度为81.5%,阴性预测值为92.2%,均高于单独检测的指标,同时特异度为79.9%,阳性预测值为59.5%,诊断效率为80.3%。结论:联合检测血清HE4和CA125有助于卵巢癌的临床诊断。
Objective: To investigate the diagnostic value of combined detection of human epididymis secretory protein 4 (HE4) and carbohydrate antigen (CA125) in ovarian cancer. Methods: The serum levels of HE4 and CA125 in 54 patients with ovarian cancer, 94 patients with benign ovarian disease and 70 healthy controls were detected by flow cytometry. The diagnostic value of single and combined detection of ovarian cancer was analyzed. Results: The combined detection of serum HE4 and CA125 was considered as positive when both of them were higher than the reference value, the sensitivity of detection was 81.5% and the negative predictive value was 92.2%, both of which were higher than those of single detection and the specificity 79.9%, the positive predictive value was 59.5% and the diagnostic efficiency was 80.3%. Conclusion: The combined detection of serum HE4 and CA125 contributes to the clinical diagnosis of ovarian cancer.